Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > Poziotinib

Poziotinib

Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), as well as HER receptor mutations; this in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors.

Target Indications

  • Currently under development for breast, lung, gastric cancer, head and neck cancer

Route of Administration

  • Oral

Mode of Action

  • Novel irreversible pan-HER Inhibitor

Status

  • An investigator sponsored trial has been initiated at the University of Texas MD Anderson Cancer Center in non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
  • Spectrum initiated a Phase 2 breast cancer program in the U.S., based on Phase 1 efficacy data in breast cancer patients who had failed multiple other HER2-directed therapies.
    Click here to view trial details on Clinical Trials.gov
  • Currently poziotinib is also being investigated in several phase 2 studies that are ongoing in Korea in multiple tumor types.
  • In March 2015, Spectrum entered into a licensing agreement with Hanmi Pharmaceutical Co., Ltd. to develop, manufacture and commercialize poziotinib worldwide excluding Korea and China.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Market Opportunities

Poziotinib

Breast Cancer

In the U.S., breast cancer is the second most common cancer in women after skin cancer. In 2016, it is estimated that there will be 246,660 new cases of female breast cancer and an estimated 40,450 people will die of this disease. It is estimated there are over 3 million women living with breast cancer, and 89.7% of these women will survive at least 5 years.

Source: Cancer.gov Website, NIH Surveillance, Epidemiology and End Result Program

Lung Cancer

Lung cancer is by far the leading cause of cancer death among both men and women; about 1 out of 4 cancer deaths are from lung cancer. In 2017, it is estimated that there will be 222,500 new cases of lung cancer and an estimated 155,870 will die of this disease. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.

Source: American Cancer Society website